CN1726189A - 新颖的mch受体拮抗剂 - Google Patents

新颖的mch受体拮抗剂 Download PDF

Info

Publication number
CN1726189A
CN1726189A CNA2003801059746A CN200380105974A CN1726189A CN 1726189 A CN1726189 A CN 1726189A CN A2003801059746 A CNA2003801059746 A CN A2003801059746A CN 200380105974 A CN200380105974 A CN 200380105974A CN 1726189 A CN1726189 A CN 1726189A
Authority
CN
China
Prior art keywords
biphenyl
ethylthiomethyl
carboxylic acid
phenoxy
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801059746A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·吉利格
L·J·海因茨
M·D·金尼克
Y－S·莱
J·M·J·莫林
N·J·斯奈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1726189A publication Critical patent/CN1726189A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2003801059746A 2002-12-11 2003-12-03 新颖的mch受体拮抗剂 Pending CN1726189A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43270102P 2002-12-11 2002-12-11
US60/432,701 2002-12-11

Publications (1)

Publication Number Publication Date
CN1726189A true CN1726189A (zh) 2006-01-25

Family

ID=32507985

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801059746A Pending CN1726189A (zh) 2002-12-11 2003-12-03 新颖的mch受体拮抗剂

Country Status (9)

Country Link
US (1) US7132456B2 (https=)
EP (1) EP1572637A1 (https=)
JP (1) JP2006509801A (https=)
CN (1) CN1726189A (https=)
AU (1) AU2003302925A1 (https=)
BR (1) BR0316948A (https=)
CA (1) CA2509042A1 (https=)
MX (1) MXPA05006272A (https=)
WO (1) WO2004052848A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
US7446204B2 (en) 2004-10-08 2008-11-04 H. Lundbeck A/S Amino substituted aryloxybenzylpiperidine derivatives
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
EP1896413B1 (en) 2005-03-28 2015-04-22 Semiconductor Energy Laboratory Co., Ltd. Anthracene derivative, material for light emitting element, light emitting element, light emitting device, and electronic device
US7731377B2 (en) * 2006-03-21 2010-06-08 Semiconductor Energy Laboratory Co., Ltd. Backlight device and display device
US7772162B2 (en) 2006-03-27 2010-08-10 Board Of Regents, The University Of Texas System Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
US20070225176A1 (en) * 2006-03-27 2007-09-27 Pope Gary A Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
EP2402320A1 (en) * 2006-03-31 2012-01-04 Novartis AG Anorectic agents
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
WO2008026614A1 (en) 2006-08-30 2008-03-06 Semiconductor Energy Laboratory Co., Ltd. Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device
WO2008118243A1 (en) * 2007-03-23 2008-10-02 Board Of Regents, The University Of Texas System Method for treating a formation with a solvent
US7723722B2 (en) * 2007-03-23 2010-05-25 Semiconductor Energy Laboratory Co., Ltd. Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative
EP2134806A4 (en) * 2007-03-23 2011-08-03 Univ Texas METHOD FOR TREATING A CARBON HYDROGEN INFORMATION
US20080286445A1 (en) * 2007-05-17 2008-11-20 Semiconductor Energy Laboratory Co., Ltd. Composition, and method of fabricating light-emitting element
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
MX2010005870A (es) * 2007-11-30 2010-08-02 Univ Texas Metodos para mejorar la productividad de pozos productores de petroleo.
WO2010005066A1 (en) * 2008-07-08 2010-01-14 Semiconductor Energy Laboratory Co., Ltd. Carbazole derivative, light-emitting element material, light-emitting element, and light-emitting device
KR101661328B1 (ko) * 2008-09-19 2016-09-29 가부시키가이샤 한도오따이 에네루기 켄큐쇼 카르바졸 유도체 및 그 제조 방법
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102844041B1 (ko) 2016-02-26 2025-08-11 가부시키가이샤 한도오따이 에네루기 켄큐쇼 유기 화합물, 발광 소자, 발광 장치, 전자 기기, 및 조명 장치
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2025101724A1 (en) 2023-11-09 2025-05-15 Chevron Phillips Chemical Company Lp Systems and methods for chromium catalyst activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535330A (en) 1968-04-29 1970-10-20 Sandoz Ag 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof
US3928449A (en) 1969-04-03 1975-12-23 Sandoz Ag Aminoalkoxy-terphenyls and the salts thereof
LU78484A1 (de) 1977-11-10 1979-06-13 Ciba Geigy Ag Verfahren zur herstellung von benzoxazolyl-phenyl-stilbenen
DE2752361A1 (de) 1977-11-24 1979-06-07 Troponwerke Gmbh & Co Kg Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
CA2509042A1 (en) 2004-06-24
WO2004052848A1 (en) 2004-06-24
US7132456B2 (en) 2006-11-07
US20060052449A1 (en) 2006-03-09
MXPA05006272A (es) 2005-08-19
BR0316948A (pt) 2005-10-18
AU2003302925A1 (en) 2004-06-30
JP2006509801A (ja) 2006-03-23
EP1572637A1 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
CN1726189A (zh) 新颖的mch受体拮抗剂
CN1157368C (zh) 人过氧化物酶体增殖剂活化受体(PPAR)α激动剂-取代苯基丙酸衍生物
CN1078889C (zh) 非肽类速激肽受体拮抗剂
CN1058969C (zh) 新的取代胍衍生物,其制备方法和其药物用途
CN1192773C (zh) 环胺ccr3拮抗剂
CN1522246A (zh) 作为微粒体甘油三酯转移蛋白(mtp)和/或载脂蛋白b(apo b)分泌抑制剂的三酰胺取代的吲哚、苯并呋喃及苯并噻吩
CN1649581A (zh) 取代的3－氨基－噻吩并[2,3－b]吡啶－2－羧酸酰胺化合物及其制备方法和用途
CN1589260A (zh) 杂环化合物和它们的使用方法
CN1443167A (zh) 用于治疗5－羟色胺相关性疾病的氮杂环化合物
CN1756746A (zh) 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1767823A (zh) 哮喘和过敏性炎症调节剂
CN1443170A (zh) 辣椒素受体配体
CN1660815A (zh) 环胺衍生物及其作为药物的用途
CN101035774A (zh) 用于治疗前列腺素d2介导的疾病的crth2受体活性调节剂
CN1901908A (zh) 治疗性化合物及其用途
CN1671659A (zh) 新的取代吲哚
CN1795193A (zh) 用作过氧化物酶体增殖物激活受体的配体的n－酰基含氮杂环化合物
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1575273A (zh) 作为cxc趋化因子受体拮抗剂的3.4－二－取代环丁烯－1,2－二酮类化合物
CN1531425A (zh) 作为整联蛋白α4的拮抗剂的脲衍生物
CN1960969A (zh) 组胺h3受体药物、其制备方法及治疗用途
CN1921848A (zh) 新型氮杂双环衍生物、其制备方法及包含其的药物组合物
CN1780815A (zh) 芳族羟苯基和芳族硫基苯基衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication